Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTY 2: Relugolix in Uterine Fibroids
NCT03103087Phase 3Completed
- Sponsor
- Myovant Sciences
- Start
- Jun 2017
- Primary completion
- Jul 2019
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of relugolix in Uterine Fibroids (UF) (3 arms), sponsored by Myovant Sciences. Primary endpoint: Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline at 24 weeks. Started Jun 2017; status: completed.
02
Drugs
relugolix
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT03103087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03103087.